**PATENT ASSIGNMENT**

**SUBMISSION TYPE:** NEW ASSIGNMENT

**NATURE OF CONVEYANCE:** Assignment of Security Interest

**CONVEYING PARTY DATA**

<table>
<thead>
<tr>
<th>Name</th>
<th>Execution Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Royalty LLC</td>
<td>03/22/2005</td>
</tr>
</tbody>
</table>

**RECEIVING PARTY DATA**

Name: HSBC Bank USA, National Association as Indenture Trustee  
Street Address: 452 Fifth Avenue  
City: New York  
State/Country: NEW YORK  
Postal Code: 10018

**PROPERTY NUMBERS** Total: 4

<table>
<thead>
<tr>
<th>Property Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent Number: 4874794</td>
<td></td>
</tr>
<tr>
<td>Patent Number: 5071879</td>
<td></td>
</tr>
<tr>
<td>Patent Number: 5534554</td>
<td></td>
</tr>
<tr>
<td>Patent Number: 5952392</td>
<td></td>
</tr>
</tbody>
</table>

**CORRESPONDENCE DATA**

Fax Number: (212)697-1559  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 2126966000  
Email: patent@cm-p.com  
Correspondent Name: Michael J. Brown/ Curtis, Mallet-Prevost  
Address Line 1: 101 Park Avenue  
Address Line 2: 34th Floor  
Address Line 4: New York, NEW YORK 10178-0061

**NAME OF SUBMITTER:** Michael J. Brown

Total Attachments: 3  
source=DRC HSBC Patent Security#page1.tif
ASSIGNMENT OF SECURITY INTEREST IN PATENTS

WHEREAS, Drug Royalty LLC, a Delaware limited liability company ("Issuer"), is the assignee of a security interest in certain patents owned by Avanir Pharmaceuticals, said security interest recorded with the U.S. Patent and Trademark Office against said patents at Reel 013608 and Frame 0920, assigned to Drug Royalty LLC by an assignment executed on March 21, 2005 and recorded with the U.S. Patent and Trademark Office on March 21, 2005, at Reel 015797 and Frame 0415, and identified on the attached Schedule A (the "Security Interest");

WHEREAS, the Issuer and HSBC Bank USA, National Association, as the Indenture Trustee, have entered into an Indenture, dated as of the date hereof (the "Indenture") whereby the Issuer has granted to the Indenture Trustee for the benefit of the Secured Parties, a first priority perfected security interest in and to all of the Issuer's right, title and interest in, among other things, the Security Interest, to secure payment of all Obligations under the Indenture and other Transaction Documents in connection with the Securitization; and

WHEREAS, the Indenture Trustee, located at 452 Fifth Avenue, New York, New York 10018, is desirous of acquiring the entire right, title and interest in the Security Interest, as part of the Collateral under the Indenture, holding such right, title and interest in its capacity as Indenture Trustee for the benefit of the Secured Parties.

In this agreement, capitalized terms which are not otherwise defined herein have the meanings given to such terms in the Indenture.

NOW THEREFORE, in consideration of the sum of ten dollars ($10.00) and other good and valuable consideration, the receipt whereof is acknowledged, Assignor, by these presents does sell, assign and transfer unto Assignee the full and exclusive right, title and interest in and to the Security Interest as Collateral.
This assignment is effective as of March 22, 2005.

DRUG ROYALTY LLC

Dated: March , 2005

By: Behzad Khosrowshahi
Name: Behzad Khosrowshahi
Title: President

HSBC BANK USA, N.A.

Dated: March , 2005

By: Wendy Zhang
Name: Wendy Zhang
Title: Assistant Vice President
Schedule A

Security Interest granted by Avanir Pharmaceuticals to Drug Royalty USA, Inc., executed on December 24, 2002 and recorded with the U.S. Patent and Trademark Office on December 26, 2002, assigned to Drug Royalty LLC by an assignment executed on March 21, 2005 and recorded with the U.S. Patent and Trademark Office on March 21, 2005, at Reel 015797 and Frame 0415, as applied to the following patents:

<table>
<thead>
<tr>
<th>Patent No.</th>
<th>Issue Date</th>
<th>Serial No.</th>
<th>Filing Date</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4874794</td>
<td>10/17/1989</td>
<td>07345084</td>
<td>04/28/1989</td>
<td>Inflammatory Disease Treatment</td>
</tr>
<tr>
<td>5071879</td>
<td>12/10/1991</td>
<td>07431304</td>
<td>11/02/1989</td>
<td>Systemic Antiviral Treatment</td>
</tr>
<tr>
<td>5534554</td>
<td>07/09/1996</td>
<td>08299944</td>
<td>09/02/1994</td>
<td>Sucrose Ester-C20 to C28 Alcohol Formulations</td>
</tr>
<tr>
<td>5952392</td>
<td>09/14/1999</td>
<td>08916624</td>
<td>08/22/1997</td>
<td>Long-Chain Alcohols, Alkanes, Fatty Acids and Amides in the Treatment of Burns and Viral Inhibition</td>
</tr>
</tbody>
</table>